Octreotide Pamoate
Duodenal Carcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Phase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Duodenal Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Solu-Cortef Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 4 | B |
Obeticholic Acid National Cancer Institute (NCI) | Phase 2 | CCC |
URSODEOXYCHOLIC ACID National Cancer Institute (NCI) | Phase 2 | CCC |
Same molecule, other indications
Octreotide Pamoate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →